在多发性骨髓瘤治疗中准NKG2D/NKG2DL轴
Zhaoyun Liu1, Hao Wang1, Hui Liu1
1Department of Hematology, Tianjin Medical University General Hospital, 154 Anshan Street, Heping District, Tianjin 300052, PR China; Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control, 154 Anshan Street, Heping District, Tianjin 300052, PR China.
多发性骨髓瘤 (MM) 治疗利用免疫细胞. 本综述探讨了NKG2D/NKG2DL轴如何影响免疫细胞,并提出了增强抗MM免疫反应的策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 免疫效应细胞对于多发性骨髓瘤 (MM) 免疫疗法至关重要.
- NKG2D受体及其配体 (NKG2DL) 在T细胞和NK细胞激活中起着关键作用.
- 通过减少NKG2DL表达,MM细胞经常逃避免疫检测.
研究的目的:
- 审查MM中NKG2D/NKG2DL轴的机制.
- 讨论加强MM中NKG2DL表达和功能的策略.
- 提出治疗方法,以改善MM的抗瘤免疫力.
主要方法:
- 在多发性髓瘤中NKG2D/NKG2DL轴研究的文献综述.
- 分析与NKG2DL表达相关的免疫逃生机制.
- 针对NKG2D/NKG2DL通路的治疗策略的合成.
主要成果:
- NKG2D/NKG2DL轴调节MM中免疫效应细胞的活动.
- 在MM中,瘤免疫逃逸涉及NKG2DL表达的降低.
- 治疗策略可能会恢复NKG2DL的表达,并增强NK细胞的功能.
结论:
- 准NKG2D/NKG2DL轴为MM免疫疗法提供了一个有希望的途径.
- 增强NKG2DL表达和抑制其脱落可以促进抗髓瘤免疫反应.
- 进一步研究调节这一轴的治疗策略是有必要的.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
